COMPANY

Stemedica Cell Technologies

HQ: San Diego, CA source · stemedica.com ↗

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: Chronic Effect of Ultraviolet Radiation on Photoaged Skin Dermatologic Disorders Alzheimer Dementia Covid19 Ischemic Stroke Allogeneic Mesenchymal Bone Marrow Cells hMSC Allogeneic adult mesenchymal bone marrow stem cells Stem cells

5Trials (company is sponsor)

Timeline

Mar 20, 2021 Trial start II: A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19 source ↗
Jun 1, 2016 Trial start Phase 2: Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease source ↗
Jul 1, 2015 Trial start Phase 1/Phase 2: Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging source ↗
2013-02 Trial start Phase 2: A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI) source ↗
2011-02 Trial start Phase 1/Phase 2: A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT01771679	Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging	Phase 1/Phase 2	Unknown status (ClinicalTrials.gov)	Jul 1, 2015	Apr 30, 2024 (estimated)
NCT02833792	Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease	Phase 2	Unknown status (ClinicalTrials.gov)	Jun 1, 2016	Jul 30, 2024 (estimated)
NCT04780685	A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19	II	Unknown status (ClinicalTrials.gov)	Mar 20, 2021	Sep 30, 2022 (estimated)
NCT01297413	A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke	Phase 1/Phase 2	Completed	2011-02	2017-09 (actual)
NCT01770613	A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)	Phase 2	Withdrawn	2013-02	2016-05 (estimated)